13F GuideFiling Basics
What is SEC Form 13F? Ultimate Guide to Institutional Equity Filings
Learn how SEC Form 13F filings work, the $100M threshold, 45-day reporting lag, and how to track top hedge fund holdings.
AlphaSMO Research GuideRead Guide
CIK: 0001388551
Total reported value
$1.9M
$1.9M
15 檔
849.5%
At the close of Q4 2024, Caxton CORP disclosed equity holdings valued at approximately $1.9M, spread across 15 reported holdings.
In Q4 2024, Caxton CORP displayed an active expansion posture, initiating 4 new positions and adding to 0 existing holdings, outstripping position reductions.
In terms of portfolio concentration, the top 5 core holdings (including XERS, RZLT, SPY) accounted for 849.5% of total reported equity market value during Q4 2024.
| # | Ticker | Issuer | Asset Subclass | Weight | Weight Change | Shares Change | 4Q Trend |
|---|---|---|---|---|---|---|---|
| 1 | XERS | Xeris Biopharma Holdings Inc | Stock-Other | 41.06% | — | -60.59% | |
| 2 | RZLT | Rezolute Inc | Stock-Other | 38.85% | — | — | |
| 3 | SPY | Ss Spdr S&p 500 ETF Trust-us | ETF-Large Cap & Growth | 9.94% | — | -1.53% | |
| 4 | BRK-B | Berkshire Hathaway Inc-cl B | Stock-Other | 3.09% | +11.69% | -1.56% | |
| 5 | GLD | Spdr Gold Shares | ETF-Commodities | 1.70% | -81.50% | EXIT | |
| 6 | BRD1EUR | Mind Medicine Mindmed Inc | Stock-Other | 1.43% | — | — | |
| 7 | BCAX | Bicara Therapeutics Inc | Stock-Other | 1.15% | — | — | |
| 8 | LXEO | Lexeo Therapeutics Inc | Stock-Other | 0.71% | +2.27% | — | |
| 9 | KYTX | Kyverna Therapeutics Inc | Stock-Other | 0.52% | +1.91% | — | |
| 10 | CMPX | Compass Therapeutics Inc | Stock-Other | 0.38% | — | — | |
| 11 | CRDF | Cardiff Oncology Inc | Stock-Other | 0.35% | — | — | |
| 12 | IKT | Inhibikase Therapeutics Inc | Stock-Other | 0.32% | +1.93% | — | |
| 13 | GLYCEUR | Glycomimetics Inc | Stock-Other | 0.31% | — | — | |
| 14 | CNTX | Context Therapeutics Inc | Stock-Other | 0.12% | — | — | |
| 15 | TORCEUR | Adicet Bio Inc | Stock-Other | 0.10% | — | — |
| # | Ticker | Issuer | Weight Change | Shares Change | Action |
|---|---|---|---|---|---|
| 1 | RZLT | Rezolute Inc | +12.4% | — | Unchanged |
| 2 | SPY | Ss Spdr S&p 500 ETF Trust-us | +3.1% | -1.53% | Trim |
| 3 | GLD | Spdr Gold Shares | +1.7% | NEW | New buy |
| 4 | BRK-B | Berkshire Hathaway Inc-cl B | +0.9% | -1.56% | Trim |
| 5 | BRD1EUR | Mind Medicine Mindmed Inc | +0.6% | — | Unchanged |
| 6 | CRDF | Cardiff Oncology Inc | +0.4% | NEW | New buy |
| 7 | IKT | Inhibikase Therapeutics Inc | +0.3% | NEW | New buy |
| 8 | GLYCEUR | Glycomimetics Inc | +0.3% | NEW | New buy |
| 9 | KYTX | Kyverna Therapeutics Inc | +0.1% | — | Unchanged |
| 10 | CMPX | Compass Therapeutics Inc | +0.1% | — | Unchanged |
| 11 | LXEO | Lexeo Therapeutics Inc | 0% | — | Unchanged |
| 12 | BCAX | Bicara Therapeutics Inc | — | — | Unchanged |
| 13 | TORCEUR | Adicet Bio Inc | — | — | Unchanged |
| 14 | CNTX | Context Therapeutics Inc | 0% | — | Unchanged |
| 15 | ABVX | Abivax Sa-adr | -0.5% | EXIT | Sold out |
| 16 | XERS | Xeris Biopharma Holdings Inc | -19.3% | -60.59% | Trim |
According to official SEC Form 13F filings, Caxton CORP reported a total U.S. public equity portfolio value of $1.9M across 15 disclosed positions in Q4 2024.
During Q4 2024, Caxton CORP's top holdings by market value included XERS (41.1%)、RZLT (38.9%)、SPY (9.9%). The largest single position, XERS, represented 41.1% of total portfolio value.
Expert Analysis & Guides for Tracking Wall Street Smart Money Movements
Learn how SEC Form 13F filings work, the $100M threshold, 45-day reporting lag, and how to track top hedge fund holdings.
Top New Position Initiated
GLD
市值: $283.1K
Top Position Liquidated / Trimmed
ABVX
前期市值: $130.9K
In Q4 2024, Caxton CORP made 8 total portfolio adjustments, initiating 4 new buys, adding to 0 positions, trimming 3 holdings, and fully liquidating 1 stocks.
All holding records on this page are fetched directly from the U.S. Securities and Exchange Commission (SEC) EDGAR system (Form 13F-HR). AlphaSMO parses CUSIP identifiers and formats data into Schema.org-compliant datasets.
Understand SEC Form 4 insider disclosures for corporate officers, directors, and 10% owners to track executive transactions.
Understand Rule 144 restricted stock sale notices to spot planned insider liquidations before market sell pressure arrives.
Explore the 5% beneficial ownership threshold, 13D vs 13G filing differences, and recent SEC accelerated deadline rules.
Best practices for analyzing 13F quarterly changes without getting misled by stock splits, options, or market valuation drift.
Learn how AlphaSMO's flagship signal detects high-conviction stocks where 13F hedge funds and corporate insiders buy at the same time.